U.S. patent number 10,604,528 [Application Number 16/315,242] was granted by the patent office on 2020-03-31 for galunisertib crystalline form, preparation method thereof and use thereof.
This patent grant is currently assigned to Crystal Pharmaceutical (Suzhou) Co., Ltd.. The grantee listed for this patent is Crystal Pharmaceutical (Suzhou) Co., Ltd.. Invention is credited to Minhua Chen, Yuhao Chen, Hui Gao, Fei Lu, Xiaoyu Zhang, Yanfeng Zhang.
United States Patent |
10,604,528 |
Chen , et al. |
March 31, 2020 |
Galunisertib crystalline form, preparation method thereof and use
thereof
Abstract
The present disclosure relates to a novel crystalline form of
Galunisertib, processes for preparation and use thereof. The
present disclosure also relates to a pharmaceutical composition
comprises the novel crystalline form of Galunisertib and use of the
novel crystalline form of Galunisertib and pharmaceutical
composition for preparing drugs treating disease. The crystalline
form of the present disclosure has good stability, solubility and
hygroscopicity, which has significant value for future drug
optimization and development. ##STR00001##
Inventors: |
Chen; Minhua (Suzhou,
CN), Zhang; Yanfeng (Suzhou, CN), Chen;
Yuhao (Suzhou, CN), Gao; Hui (Suzhou,
CN), Lu; Fei (Suzhou, CN), Zhang;
Xiaoyu (Suzhou, CN) |
Applicant: |
Name |
City |
State |
Country |
Type |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Suzhou, Jiangsu |
N/A |
CN |
|
|
Assignee: |
Crystal Pharmaceutical (Suzhou)
Co., Ltd. (Suzhou, CN)
|
Family
ID: |
60912012 |
Appl.
No.: |
16/315,242 |
Filed: |
July 21, 2017 |
PCT
Filed: |
July 21, 2017 |
PCT No.: |
PCT/CN2017/092233 |
371(c)(1),(2),(4) Date: |
January 04, 2019 |
PCT
Pub. No.: |
WO2018/006870 |
PCT
Pub. Date: |
January 11, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20190241572 A1 |
Aug 8, 2019 |
|
Foreign Application Priority Data
|
|
|
|
|
Jul 7, 2016 [CN] |
|
|
201610533326 |
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D
487/04 (20130101); A61P 35/00 (20180101); A61K
31/4709 (20130101); A61K 31/4162 (20130101); C07B
2200/13 (20130101) |
Current International
Class: |
C07D
487/04 (20060101); A61K 31/4162 (20060101); A61P
35/00 (20060101); A61K 31/4709 (20060101) |
Field of
Search: |
;546/167 ;514/314 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
1714090 |
|
Dec 2005 |
|
CN |
|
2007/018818 |
|
Feb 2007 |
|
WO |
|
Other References
CMU Pharmaceutical polymorphism, internet p. 1-3 (2002) printout
Apr. 3, 2008. cited by examiner .
Singhal et al., "Drug Polymorphism, etc.," Advanced Drug Delivery
reviews 56, p. 335-347 (2004). cited by examiner .
Concise Encyclopedia Chemistry, NY: Walter de Gruyter, 1993,
872-873. cited by examiner .
Jain et al., "Polymorphism in Pharmacy", Indian Drugs, 1986, 23(6)
315-329. cited by examiner .
Muzaffar et al., "Polymorphism and Drug Availability, etc.," J of
Pharm. (Lahore), 1979, 1(1), 59-66. cited by examiner .
U.S. Pharmacopia #23, National Formulary #18, 1995, 1843-1844.
cited by examiner .
Doelker, english translation of S.T.P, Pratiques (1999), 9(5),
399-409, pp. 1-33. cited by examiner .
Doelker, english translation of Ann. Pharm. Fr., 2002, 60: 161-176,
pp. 1-39. cited by examiner .
Taday et al., "Using Terahertz, etc.," J of Pharm. Sci., 92(4),
2003, 831-838. cited by examiner .
Osuka et al., "Effect of Polymorphic, etc.," Chem. Pharm. Bull.,
47(6) 852-856 (1999). cited by examiner .
Niemeier et al., Application of Kinetic Modeling and Competitive
Solvent Hydrolysis in the Development of a Highly Selective
Hydrolysis of a Nitrile to an Amide. Org Process Res Dev.
2014;18(3):410-416. cited by applicant .
International Search Report and Written Opinion for Application No.
PCT/CN2017/092233, dated Sep. 28, 2017, 10 pages. cited by
applicant.
|
Primary Examiner: Morris; Patricia L
Attorney, Agent or Firm: McCarter & English, LLP Davis;
Steven G. Song; Wei
Claims
What is claimed is:
1. A crystalline form A of Galunisertib, wherein the X-ray powder
diffraction pattern shows characteristic peaks at 2theta values of
22.0.degree..+-.0.2.degree., 10.4.degree..+-.0.2.degree. and
25.3.degree..+-.0.2.degree. using CuK.alpha. radiation.
2. The crystalline form A according to claim 1, wherein the X-ray
powder diffraction pattern shows 1 or 2 or 3 characteristic peaks
at 2theta values of 15.9.degree..+-.0.2.degree.,
14.7.degree..+-.0.2.degree. and 16.9.degree..+-.0.2.degree. using
CuK.alpha. radiation.
3. The crystalline form A according to claim 1, wherein the X-ray
powder diffraction pattern shows 1 or 2 or 3 characteristic peaks
at 2theta values of 19.5.degree..+-.0.2.degree.,
12.5.degree..+-.0.2.degree. and 20.0.degree..+-.0.2.degree. using
CuK.alpha. radiation.
4. The crystalline form A according to claim 2, wherein the X-ray
powder diffraction pattern shows 1 or 2 or 3 characteristic peaks
at 2theta values of 19.5.degree..+-.0.2.degree.,
12.5.degree..+-.0.2.degree. and 20.0.degree..+-.0.2.degree. using
CuK.alpha. radiation.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a U.S. national stage application, filed
under 35 U.S.C. .sctn. 371(c), of International Application No.
PCT/CN2017/092233, filed on Jul. 21, 2017, which claims the
priority of Chinese Application No. 201610533326.X, filed on Jul.
7, 2016. The entire contents of the aforementioned applications are
incorporated herein by reference.
TECHNICAL FIELD
The present disclosure relates to the technical field of
pharmaceutical crystal technology, particularly relates to the
novel crystalline form of Galunisertib, processes for preparation
and use thereof.
BACKGROUND
Transforming growth factor-.beta. (TGF-.beta.) is a pleiotropic
cytokine with multiple tumor supporting effects, including
angiogenesis and immunosuppression. The increase of TGF-.beta.
expression is closely related to the progression of various tumors
and poor clinical prognosis. Expression of TGF-.beta. promotes
tumor growth, inhibits the immune system, and enhances tumor
spread.
Galunisertib (LY-2157299) is a TGF-.beta. kinase inhibitor
developed by Eli Lilly, which has the potential to treat
myelodysplastic syndromes and solid tumors. The chemical name of
Galunisertib is
2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrol-
o[1,2-b]pyrazole, and the structure is shown in formula I.
##STR00002##
Polymorph or polymorphism is a particular property of certain
molecule and molecular composition. Different crystalline forms of
certain compounds arise from different molecular packing in the
crystal lattice, and these crystalline forms have different crystal
structures and physical properties, such as solubility; stability,
thermal property, mechanical property, purification capability,
X-ray diffraction pattern, infrared absorption spectroscopy, Raman
spectroscopy, solid state nuclear magnetic resonance, etc. One or
more analytical techniques can be used to distinguish different
crystalline forms of the same molecule or molecular
composition.
Novel crystalline forms (including anhydrates, hydrates and
solvates) of the active pharmaceutical ingredients may offer better
processing and physicochemical properties, such as bioavailability,
stability, processability, and purification ability. Some novel
crystalline forms may serve as intermediate crystal forms to
facilitate solid state transformation to desired forms. Novel
polymorphs of raw materials provide more solid forms in the
formulation, and this can improve dissolution, improve shelf life,
and make it easier to process.
A monohydrate crystalline form of Galunisertib (designated as Form
1 in the present disclosure) was disclosed in the patent
application WO2007018818A1, which is hereby incorporated by
reference. The X-ray powder diffraction pattern of Form 1 shows one
or more characteristic peaks at 2theta values of 9.05.degree.,
11.02.degree..+-.0.1.degree., 11.95.degree..+-.0.1.degree., and
14.84.degree..+-.0.1.degree.. However, the inventors of the present
disclosure found an anhydrous crystalline form of Galunisertib
(hereinafter referred to as Form A) during the research. The X-ray
powder diffraction pattern of Form A shows characteristic peaks at
2theta values of 22.0.degree..+-.0.2.degree.,
10.4.degree..+-.0.2.degree., and 25.3.degree..+-.0.2.degree..
Compared with the monohydrate Form 1 of the prior art, it has been
found that Form A of the present disclosure has better solubility,
hygroscopicity and stability. When Form 1 and Form A are placed in
80% RH, Form 1 is slightly hygroscopic. While Form A is
non-hygroscopic or almost non-hygroscopic. In particular, Form A
has a significant improvement in solubility compared to Form 1 of
the prior art. For example, in FaSSIF (Fasted state simulated
intestinal fluids, pH=6.5), the solubility of Form A is ten times
higher than that of Form 1 at 24 h. The increase in solubility is
beneficial to reduce drug load and improve the bioavailability of
the drug products. No form change was observed for Form A of the
present disclosure after being placed at 40.degree. C./75% RH for
one year or mechanical grinding, which indicates that Form A has
good stability. Good stability can effectively avoid crystal
transformation during drug storage and development, thus avoiding
changes in bioavailability and efficacy.
SUMMARY
In order to overcome the disadvantages of prior arts, the main
objective of the present disclosure is to provide a novel
crystalline form of Galunisertib, processes for preparation and use
thereof.
According to the objective of the present disclosure, a novel
crystalline form of Galunisertib is provided (hereinafter referred
to as Form A). The crystalline form of the present disclosure has
high solubility, is almost non-hygroscopic and has good stability,
which is suitable for industrial purification and production. Form
A provided by the present disclosure is an anhydrite.
According to one aspect of the present disclosure, the X-ray powder
diffraction pattern of Form A shows characteristic peaks at 2theta
values of 22.0.degree..+-.0.2.degree., 10.4.degree..+-.0.2.degree.
and 25.3.degree..+-.0.2.degree. using CuK.alpha. radiation.
Furthermore, the X-ray powder diffraction pattern of Form A shows 1
or 2 or 3 characteristic peaks at 2theta values of
15.9.degree..+-.0.2.degree., 14.7.degree..+-.0.2.degree. and
16.9.degree..+-.0.2.degree.. Preferably, the X-ray powder
diffraction pattern of Form A shows characteristic peaks at 2theta
values of 15.9.degree..+-.0.2.degree., 14.7.degree..+-.0.2.degree.
and 16.9.degree..+-.0.2.degree..
Furthermore, the X-ray powder diffraction pattern of Form A shows 1
or 2 or 3 characteristic peaks at 2theta values of
19.5.degree..+-.0.2.degree., 12.5.degree..+-.0.2.degree. and
20.0.degree..+-.0.2.degree.. Preferably, the X-ray powder
diffraction pattern of Form A shows characteristic peaks at 2theta
values of 19.5.degree..+-.0.2.degree., 12.5.degree..+-.0.2.degree.
and 20.0.degree..+-.0.2.degree..
In a preferred embodiment, the X-ray powder diffraction pattern of
Form A shows characteristic peaks at 2theta values of
22.0.degree..+-.0.2.degree., 10.4.degree..+-.0.2.degree.,
25.3.degree..+-.0.2.degree., 15.9.degree..+-.0.2.degree.,
14.7.degree..+-.0.2.degree., 16.9.degree..+-.0.2.degree.,
19.5.degree..+-.0.2.degree., 12.5.degree..+-.0.2.degree. and
20.0.degree..+-.0.2.degree..
Without any limitation being implied, in a specific example of the
present disclosure, the X-ray powder diffraction pattern of Form A
is substantially as depicted in FIG. 1.
According to the objective of the present disclosure, a process for
preparing Form A is also provided. The process comprises: heating
the solid of Galunisertib to 170.degree. C.-240.degree. C., and the
obtained solid is Form A.
Preferably, said heating is heating to 180.degree. C.
In the present disclosure, "crystal" or "crystalline form" refers
to the crystal or the crystal form being identified by the X-ray
diffraction pattern shown herein. Those skilled in the art are able
to understand that physicochemical properties discussed herein can
be characterized, wherein the experimental errors depend on the
conditions of instruments, the sampling processes and the purity of
samples. In particular, those skilled in the art generally know
that the X-ray diffraction pattern typically vary with the
experimental conditions. It is necessary to point out that, the
relative intensity of the diffraction peaks in the X-ray
diffraction pattern may also vary with the experimental conditions;
therefore, the order of the diffraction peak intensities cannot be
the sole or decisive factor. In fact, the relative intensity of the
diffraction peaks in the X-ray powder diffraction pattern is
related to the preferred orientation of the crystals, and the
diffraction peak intensities shown herein are illustrative and not
for absolute comparison. In addition, the experimental error of the
diffraction peak position is usually 5% or less, and the error of
the position should also be taken into account, and an error of
.+-.0.2.degree. is usually allowed. In addition, due to
experimental factors such as sample thickness, the overall offset
of the diffraction peak happened, and a certain offset is usually
allowed. Thus, it will be understood by those skilled in the art
that it is unnecessary that the X-ray diffraction pattern of a
crystalline form of the present disclosure should be exactly the
same as X-ray diffraction patterns of the example shown herein. Any
crystalline forms whose X-ray diffraction patterns have the same or
similar characteristic peaks should be within the scope of the
present disclosure. Those skilled in the art can compare the
patterns shown in the present disclosure with that of an unknown
crystalline form in order to identify whether these two groups of
patterns reflect the same or different crystalline forms.
In some embodiments, crystalline Form A of the present disclosure
is pure, singular and substantially free of any other crystalline
forms. In the present disclosure, the term "substantially free"
when used to describe a novel crystalline form, it means that the
content of other crystalline forms in the novel crystalline form is
less than 20% (w/w), specifically less than 10% (w/w), more
specifically less than 5% (w/w) and further more specifically less
than 1% (w/w).
According to the objective of the present disclosure, a
pharmaceutical composition is provided;
said pharmaceutical composition comprises a therapeutically and/or
preventively effective amount of Form A and pharmaceutically
acceptable carriers, diluents or excipients.
Furthermore, Form A of the present disclosure can be used for
preparing drugs treating myelodysplastic syndromes.
Furthermore, Form A of the present disclosure can be used for
preparing drugs treating solid tumors.
Furthermore, said pharmaceutical composition may also contain other
pharmaceutically acceptable crystalline forms or amorphous of
Galunisertib or salts thereof, including but not limited to, for
example Form 1 disclosed in WO2007018818A1.
The Galunisertib Form A of the present disclosure has the following
advantages:
Good solubility. The solubility of Form A in three buffers with
different pH values is higher than that of Form 1 of the prior
art;
Good stability. No form change was observed for Form A after being
placed at 40.degree. C./75% RH for one year or mechanical grinding.
Form A has better stability than Form 1 at high temperature.
Non-hygroscopic or almost non-hygroscopic. Compared with Form 1 of
the prior art, Form A has lower hygroscopicity. Form A is not
susceptible to high humidity to deliquescence, which is beneficial
for long-term storage of the drug.
Crystalline form with low hygroscopicity does not require special
drying conditions in the preparation process, which simplifies the
preparation and downstream process, and is easy for industrial
production. Moreover, the water content of Form A remains
substantially unchanged under different humidity conditions, which
is beneficial to the long-term storage of the drug. Due to the
non-strict requirements on storage conditions, the cost of drug
storage and quality control will be greatly reduced, which has
great economic value. Higher solubility helps to improve the
absorption and availability of drugs in the body, improve drug
efficacy and bioavailability.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows an XRPD pattern of Form A in example 1.
FIG. 2 shows a DSC curve of Form A in example 1.
FIG. 3 shows a TGA curve of Form A in example 1.
FIG. 4 shows a NMR spectrum of Form A in example 1.
FIG. 5 shows a DVS plot of Form A in example 2.
FIG. 6 shows a DVS plot of Form 1 in example 2.
FIG. 7 shows the XRPD pattern overlay of Form A before and after
DVS in example 2 (top: XRPD pattern before DVS test, bottom: XRPD
pattern after DVS test).
FIG. 8 shows the XRPD pattern overlay of Form 1 before and after
DVS in example 2 (top: XRPD pattern before DVS test, bottom: XRPD
pattern after DVS test).
FIG. 9 shows the XRPD pattern overlay of Form A before and after
grinding in example 5 (top: XRPD pattern before grinding, bottom:
XRPD pattern after grinding).
FIG. 10 shows the XRPD pattern overlay of Form A before and after
stability test in example 6 (from top to bottom: the initial Form A
and samples of Form A stored at 25.degree. C./60% RH for 12 months,
40.degree. C./75% RH for 12 months, 60.degree. C./75% RH for 2
weeks, and 80.degree. C. for 2 weeks.)
FIG. 11 shows the XRPD pattern overlay of Form 1 before and after
stability test in example 6 (from top to bottom: the initial From 1
and Form 1 stored at 25.degree. C./60% RH for 12 months, Form 1
stored at 40.degree. C./75% RH for 12 months, Form 1 stored at
60.degree. C./75% RH for 2 weeks, Form 1 stored at 80.degree. C.
for 2 weeks and the initial Form A.)
DETAILED DESCRIPTION OF THE PRESENT DISCLOSURE
The present disclosure is further illustrated by the following
examples which describe the preparation and use of the crystalline
forms of the present disclosure in detail. It is obvious to those
skilled in the art that many changes in the materials and methods
can be accomplished without departing from the scope of the present
disclosure.
Instruments and methods used to collect data:
The abbreviations used in the present disclosure are explained as
follows:
XRPD: X-ray Powder Diffraction
DSC: Differential Scanning Calorimetry
TGA: Thermal Gravimetric Analysis
DVS: Dynamic Vapor Sorption
.sup.1H NMR: Proton Nuclear Magnetic Resonance
PSD: Particle Size Distribution
HPLC: High Performance Liquid Chromatography
X-ray powder diffraction pattern the present disclosure was
acquired by a Panalytical Empyrean X-ray powder diffractometer. The
parameters of the X-ray powder diffraction method of the present
disclosure were as follows:
X-ray Reflection: Cu, K.alpha.
K.alpha.1 (.ANG.): 1.540598; K.alpha.2 (.ANG.): 1.544426
K.alpha.2/K.alpha.1 intensity ration: 0.50
Voltage: 45 (kV)
Current: 40 (mA)
Scan range: from 3.0 degree to 40.0 degree
Differential scanning calorimetry (DSC) data in the present
disclosure were acquired by a TA Q2000. The parameters of the
differential scanning calorimetry (DSC) method of the present
disclosure were as follows:
Heating rate: 10.degree. C./min
Purge gas: nitrogen
Thermal gravimetric analysis (TGA) data in the present disclosure
are acquired by a TA Q5000. The parameters of the thermal
gravimetric analysis (TGA) method of the present disclosure were as
follow:
Heating rate: 10.degree. C./min
Purge gas: nitrogen
Proton nuclear magnetic resonance spectrum data (.sup.1H NMR) was
collected from a Bruker Avance II DMX 400M HZ NMR spectrometer. 1-5
mg of sample was weighed, and dissolved in 0.5 mL of deuterated
dimethyl sulfoxide to obtain a solution with a concentration of
2-10 mg/ML.
Unless otherwise specified, the following examples were conducted
at room temperature
The particle size distribution test in the present disclosure is
acquired by the S3500 laser particle size analyzer of Microtrac.
Microtrac S3500 is equipped with the SDC (Sample Delivery
Controller). The test is carried out by wet process, and the
dispersion medium is Isopar G. The parameters are as follow:
TABLE-US-00001 Size distribution: Volume Run Time: 10 s Dispersion
medium: Isopar G Particle coordinates: Standard Run Number: Average
of 3 runs Fluid refractive index: 1.42 Particle Transparency: Trans
Residuals: Enabled Particle refractive index: 1.59 Flow rate: 60*
Particle shape: Irregular Filtration: Enabled *Flow rate 60% is 60%
of 65 mL/s.
Raw materials of Galunisertib used in the following examples are
prepared by known methods in the prior art, for example, the method
disclosed in WO2007018818A.
Example 1: Preparation of Form A
207.7 mg of Galunisertib solid was weighed into a 20-mL glass vial.
The glass vial was placed into an oven at 180.degree. C. for two
hours and the solid was collected.
The obtained solid in this example was confirmed to be Form A. The
X-ray powder diffraction data of the obtained solid are shown in
Table 1, while the XRPD pattern is substantially as depicted in
FIG. 1.
TABLE-US-00002 TABLE 1 2.theta. d spacing Relative intensity % 9.42
9.39 12.85 10.35 8.55 80.20 11.27 7.85 24.24 12.54 7.06 24.48 14.69
6.03 39.47 15.36 5.77 8.26 15.92 5.57 43.90 16.94 5.23 36.21 17.39
5.10 13.66 17.99 4.93 14.59 19.48 4.56 32.54 19.96 4.45 25.28 20.48
4.34 12.00 20.82 4.27 19.68 21.09 4.21 16.95 22.04 4.03 100.00
22.31 3.99 23.46 23.28 3.82 29.94 23.56 3.78 28.32 24.13 3.69 9.79
24.55 3.63 3.98 25.25 3.53 59.45 25.62 3.48 21.16 26.78 3.33 2.90
27.22 3.28 1.78 28.03 3.18 3.50 29.40 3.04 2.58 30.75 2.91 5.46
31.22 2.86 4.08 33.92 2.64 3.15 35.23 2.55 5.58 36.13 2.49 1.53
36.59 2.46 1.07 37.69 2.39 3.43 38.31 2.35 1.78 39.56 2.28 1.29
When differential scanning calorimetry (DSC) was performed on Form
A, an endothermic peak appeared with onset temperature at around
247.degree. C., and the DSC curve is substantially as depicted in
FIG. 2.
When thermo gravimetric analysis (TGA) was performed on Form A,
about 1.8% weight loss was observed when Form A was heated to
150.degree. C., and the TGA curve is substantially as depicted in
FIG. 3.
The .sup.1H NMR spectrum of Form A is substantially as depicted in
FIG. 4, and the corresponding data are: .sup.1H NMR (400 MHz,
DMSO-d.sup.6): .delta. 8.88 (d, J=4.2 Hz, 1H), 8.25 (s, 1H), 8.12
(d, J=7.2 Hz, 1H), 8.03 (d, J=11.9 Hz, 2H), 7.58 (d, J=3.7 Hz, 2H),
7.41 (d, J=3.4 Hz, 1H), 7.34 (s, 1H), 6.93 (s, 1H), 4.31 (s, 2H),
2.83 (s, 2H), 2.64 (s, 2H), 1.75 (s, 3H).
Example 2: Hygroscopicity of Form A
Dynamic vapor sorption (DVS) was applied to test hygroscopicity of
Form A and Form 1 disclosed in WO2007018818A1 with about 10 mg of
samples. The results are listed in Table 2.
TABLE-US-00003 TABLE 2 Relative humidity (RH) Weight Weight gain at
80% gain at Crystalline form RH 95% RH Solid Form after DVS test
Form 1 0.33% 0.53% Form 1 (slightly amorphous) Form A 0.15% 0.23%
Form A (no change)
The DVS plots of Form A and Form 1 are substantially as depicted in
FIG. 5 and FIG. 6. The XRPD pattern overlay of Form A and Form 1
before and after DVS is substantially as depicted in FIG. 7 and
FIG. 8 (top: XRPD pattern before DVS test, bottom: XRPD pattern
after DVS test).
Description and definition of hygroscopicity (Chinese Pharmacopoeia
2015 edition, 9103 General drug hygroscopic test guidelines, test
at 25.degree. C..+-.1.degree. C., 80% RH).
Deliquescent: Sufficient water is absorbed to form a liquid;
Very hygroscopic: Increase in mass is equal to or greater than 15
percent;
Hygroscopic: Increase in mass is less than 15 percent and equal to
or greater than 2 percent;
Slightly hygroscopic: Increase in mass is less than 2 percent and
equal to or greater than 0.2 percent.
Non-hygroscopic or almost non-hygroscopic: increase in mass is less
than 0.2%.
Weight gain of Form A at 80% RH is 0.15%. Form A is non-hygroscopic
or almost non-hygroscopic. Weight gain of Form 1 of the prior art
at 80% RH is 0.33%. Form 1 is slightly hygroscopic. The
hygroscopicity of Form A is superior to that of Form 1 of the prior
art. Form A is not susceptible to high humidity to
deliquescence.
The XRPD results show that the crystalline form of Form A of the
present disclosure does not change after DVS test and keeps good
crystallinity. After DVS test, Form A maintains stable
physicochemical properties, which is suitable for drug preparation,
storage and production process.
Example 3: Kinetic Solubility
Form A of the present disclosure and Form 1 of the prior art were
suspended into FaSSIF (Fasted state simulated intestinal fluids,
pH=6.5), FeSSIF (Fed state simulated intestinal fluids, pH=5.0),
SGF (Simulated gastric fluids, pH=1.8) and water to get saturated
solutions. After equilibrated for 1 h, 4 h and 24 h, concentrations
of the saturated solutions were measured by HPLC. The results are
listed in Table 3.
TABLE-US-00004 TABLE 3 results of kinetic solubility experiment
FaSSIF FeSSIF H.sub.2O Form Form Form Form Form Form time 1 A 1 A 1
A solubility 1 h 0.058 0.23 0.12 0.48 0.056 0.17 (mg/mL) 4 h 0.051
0.27 0.11 0.82 0.055 0.25 24 h 0.052 0.52 0.12 0.64 0.055 0.31
From the results of kinetic solubility in Table 53, the solubility
of Form A of the present disclosure is significantly higher than
that of the prior art Form 1 at each sampling point. The solubility
of Form 1 is less than 0.06 mg/mL in both FaSSIF and H.sub.2O. The
solubility of Form A of the present disclosure is 3 to 10 times
higher than that of Form 1 in FaSSIF and H.sub.2O, and 4 to 8 times
higher than that of Form 1 in FeSSIF, indicating that Form A has
better solubility in FaSSIF, FeSSIF and water, and Form A has
achieved unexpected effects.
Example 4: Particle Size Comparison Experiment
The results of particle size distribution are shown in table 4
TABLE-US-00005 TABLE 4 particle size distribution Solid
Ultrasonication MV form time (s) (.mu.m) D10 (.mu.m) D50 (.mu.m)
D90 (.mu.m) Form 1 0 62.25 33.41 56.97 95.11 30 45.75 24.89 42.56
68.40 60 40.41 22.40 37.88 59.87 90 37.83 20.94 35.58 55.95 Form A
0 190.8 50.28 170.3 356.4 30 116.1 34.37 106.2 210.5 60 104.1 29.37
92.81 192.2 90 91.94 26.40 83.69 167.2
The abbreviations used in the present disclosure are explained as
follows:
MV: Average particle size calculated by volume
D10: particle size which accounts for 10% of the particle size
distribution (volume distribution)
D50: particle size which accounts for 50% of the particle size
distribution (volume distribution)
D90: particle size which accounts for 90% of the particle size
distribution (volume distribution)
The results show that Form A of the present disclosure has a larger
particle size. An increase in particle size in the production
process is beneficial for product separation, filtration and
purification.
Example 5: Mechanical Stability
Solid sample of Form A of the present disclosure was ground
manually for 5 minutes in mortar. The XRPD pattern overlay of the
solids before and after grinding is substantially as depicted in
FIG. 9 (top: XRPD pattern before grinding, bottom: XRPD pattern
after grinding). The XRPD pattern doesn't change significantly
before and after grinding, indicating that Form A can maintain
stable physicochemical properties under certain mechanical
stress.
Example 6: Long-Term and Accelerated Stability
Solid samples of Form A and Form 1 were stored under different
conditions of 25.degree. C./60% RH, 40.degree. C./75% RH.
60.degree. C./75% RH and 80.degree. C. The results are shown in
Table 5
TABLE-US-00006 TABLE 5 stability experiment results Initial form
Conditions Time Solid form Form 1 25.degree. C./60% RH 12 months
Form 1 40.degree. C./75% RH 12 months Form 1 60.degree. C./75% RH 2
weeks Form 1 80.degree. C. 2 weeks Form 1 + Form A Form A
25.degree. C./60% RH 12 months Form A 40.degree. C./75% RH 12
months Form A 60.degree. C./75% RH 2 weeks Form A 80.degree. C. 2
weeks Form A
The results show that form A keeps stable for at least 12 months at
25.degree. C./60% RH and 40.degree. C./75% RH, at least 2 weeks at
60.degree. C./75% RH and 80.degree. C., indicating that Form A has
good stability at room temperature/high temperature/high humidity
conditions. However, the stability of Form 1 at high temperature is
poor. Form 1 partially converts to Form A after being stored at
80.degree. C. for two weeks. The XRPD overlays of Form A and Form 1
under different conditions are substantially as depicted in FIG. 10
and FIG. 11, respectively.
The examples described above are only for illustrating the
technical concepts and features of the present disclosure, and
intended to make those skilled in the art being able to understand
the present disclosure and thereby implement it, and should not be
concluded to limit the protective scope of this disclosure. Any
equivalent variations or modifications according to the spirit of
the present disclosure should be covered by the protective scope of
the present disclosure
* * * * *